Published in BMJ Case Rep on November 21, 2012
Acute disseminated encephalomyelitis. Neurology (2007) 2.84
The Canadian Neurological Scale: validation and reliability assessment. Neurology (1989) 1.78
Acute disseminated encephalomyelitis: an acute hit against the brain. Curr Opin Neurol (2007) 1.34
Mycoplasma pneumoniae-associated myelitis: a comprehensive review. Eur J Neurol (2006) 1.04
Mycoplasma pneumoniae infection associated with an acute brainstem syndrome. Acta Neurol Scand (1996) 0.93
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res (2003) 8.06
Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol (2008) 7.79
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery (2008) 5.03
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol (2010) 5.03
Lyme borreliosis. Lancet Infect Dis (2003) 4.58
Long-term survival with glioblastoma multiforme. Brain (2007) 4.51
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol (2009) 4.32
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol (2011) 3.66
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol (2009) 3.65
Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol (2014) 3.52
Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol (2009) 3.38
Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol (2006) 3.38
Microsurgical resection of Spetzler-Martin grades 1 and 2 unruptured brain arteriovenous malformations results in lower long-term morbidity and loss of quality-adjusted life-years (QALY) than conservative management--results of a single group series. Acta Neurochir (Wien) (2015) 3.23
Chemotherapy-induced peripheral neuropathy. J Neurol (2002) 3.09
Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol (2009) 2.77
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol (2006) 2.62
Acute disseminated encephalomyelitis: an update. Arch Neurol (2005) 2.45
Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis (2010) 2.32
Mechanical recanalization in basilar artery occlusion: the ENDOSTROKE study. Ann Neurol (2015) 2.16
Symptomatic acute occlusion of the internal carotid artery: reappraisal of urgent vascular reconstruction based on current stroke imaging. J Vasc Surg (2008) 2.11
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology (2013) 2.02
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol (2013) 2.00
Desmoplastic infantile astrocytoma with multiple intracranial and intraspinal localizations at presentation. Childs Nerv Syst (2015) 2.00
Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol (2009) 1.93
Chronic inflammatory demyelinating polyneuropathy. N Engl J Med (2005) 1.79
Microscope-integrated quantitative analysis of intraoperative indocyanine green fluorescence angiography for blood flow assessment: first experience in 30 patients. Neurosurgery (2012) 1.77
Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol (2004) 1.69
Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. J Neurol Neurosurg Psychiatry (2012) 1.66
Induction of Nrf2 and xCT are involved in the action of the neuroprotective antibiotic ceftriaxone in vitro. J Neurochem (2009) 1.63
Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry (2013) 1.63
Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res (2009) 1.61
Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol (2002) 1.61
The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol (2011) 1.58
Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology (2013) 1.56
Quality control after cochlear implant surgery by means of rotational tomography. Otol Neurotol (2005) 1.54
Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle (2013) 1.52
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol (2010) 1.52
Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol (2013) 1.49
Extreme phenotypic variability in a German family with X-linked myotubular myopathy associated with E404K mutation in MTM1. Neuromuscul Disord (2006) 1.46
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler (2012) 1.46
Quinpramine is a novel compound effective in ameliorating brain autoimmune disease. Exp Neurol (2008) 1.44
Neuromyelitis optica following human papillomavirus vaccination. Neurology (2012) 1.44
Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs (2014) 1.44
Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol (2014) 1.42
Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis. Dev Med Child Neurol (2009) 1.42
[A 64-year old woman with otitis media, splenic infarction and pareses]. Tidsskr Nor Laegeforen (2008) 1.38
Analysis of astroglial K+ channel expression in the developing hippocampus reveals a predominant role of the Kir4.1 subunit. J Neurosci (2009) 1.38
Acute disseminated encephalomyelitis: an acute hit against the brain. Curr Opin Neurol (2007) 1.34
Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol (2010) 1.34
Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. Acta Neuropathol (2010) 1.32
2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int J Cancer (2011) 1.31
CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol (2012) 1.31
Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol (2013) 1.27
European multicenter study of the AcrySof ReSTOR apodized diffractive intraocular lens. Ophthalmology (2006) 1.26
An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. J Clin Invest (2011) 1.25
Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs (2008) 1.25
Recurrent symptomatic high-grade intracranial stenoses: safety and efficacy of undersized stents--initial experience. Radiology (2004) 1.25
Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol (2009) 1.24
Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol (2005) 1.23
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathol (2012) 1.22
Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS One (2012) 1.19
Estimating cancer survival and clinical outcome based on genetic tumor progression scores. Bioinformatics (2005) 1.18
Connexin expression by radial glia-like cells is required for neurogenesis in the adult dentate gyrus. Proc Natl Acad Sci U S A (2009) 1.17
Cerebrospinal fluid HIV viral load in different phases of HIV-associated brain disease. J Neurol (2005) 1.17
Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme. Neuro Oncol (2007) 1.17
Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. Arch Neurol (2006) 1.17
Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Int J Radiat Oncol Biol Phys (2009) 1.16
Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol (2015) 1.16
Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol (2013) 1.15
From bench to bedside--experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol (2007) 1.14
IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol (2015) 1.13
Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol (2005) 1.13
Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat (2009) 1.12
Lack of IL-6 augments inflammatory response but decreases vascular permeability in bacterial meningitis. Brain (2003) 1.12
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol (2010) 1.11
Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis (2005) 1.11
The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis. EMBO Mol Med (2011) 1.10
Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol (2007) 1.09
Primary meningeal osteosarcoma: case report and review of the literature. Neurosurgery (2002) 1.09
Morphologic changes in the vastus medialis muscle in patients with osteoarthritis of the knee. Arthritis Rheum (2007) 1.09
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler (2012) 1.09
Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord (2010) 1.08
Viral load determines the B-cell response in the cerebrospinal fluid during human immunodeficiency virus infection. Ann Neurol (2007) 1.08
Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Int J Cancer (2011) 1.08
MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. Neoplasia (2007) 1.07
Cytotoxic CD8+ T cell-neuron interactions: perforin-dependent electrical silencing precedes but is not causally linked to neuronal cell death. J Neurosci (2009) 1.07
Photoreceptor layer thinning in parkinsonian syndromes. Mov Disord (2014) 1.07
Charcot-Marie-Tooth disease CMT4A: GDAP1 increases cellular glutathione and the mitochondrial membrane potential. Hum Mol Genet (2011) 1.07
Passive immunization with anti-ganglioside antibodies directly inhibits axon regeneration in an animal model. J Neurosci (2007) 1.07
Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors. Acta Neuropathol (2003) 1.07
Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. Acta Neuropathol (2009) 1.06
Peripheral neuropathy: assessment of proximal nerve integrity by diffusion tensor imaging. Muscle Nerve (2013) 1.06
Phosphoinositide 3-kinases upregulate system xc(-) via eukaryotic initiation factor 2α and activating transcription factor 4 - A pathway active in glioblastomas and epilepsy. Antioxid Redox Signal (2014) 1.05
Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res (2007) 1.03
Subclassification of nerve sheath tumors by gene expression profiling. Brain Pathol (2004) 1.03
AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. Acta Neuropathol (2013) 1.03
Multiple meningiomas: Investigating the molecular basis of sporadic and familial forms. Int J Cancer (2003) 1.02